Abstract
Natesh Singh
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
No local citing links have been materialized yet.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
10.1038/s41564-020-0695-z · 2020
10.1016/j.it.2020.10.004
10.1016/j.it.2020.10.004
10.1016/j.cell.2020.02.052
10.1016/j.cell.2020.02.052
10.1016/j.cell.2020.04.011
10.1016/j.cell.2020.04.011
10.1016/s0140-6736(20)30251-8
10.1016/s0140-6736(20)30251-8
10.1038/s41586-020-2012-7
10.1038/s41586-020-2012-7
10.1021/acs.jmedchem.0c00606
10.1021/acs.jmedchem.0c00606
10.1021/acsinfecdis.0c00701
10.1021/acsinfecdis.0c00701
10.1111/cei.13087
10.1111/cei.13087
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
2020
10.1016/s0140-6736(20)30183-5
10.1016/s0140-6736(20)30183-5
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1016/j.smim.2013.11.002
10.1016/j.smim.2013.11.002
10.2217/imt-2016-0020
10.2217/imt-2016-0020
10.1016/j.ijantimicag.2020.105954
10.1016/j.ijantimicag.2020.105954
Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
10.3389/fimmu.2020.01022 · 2020
10.1038/s41572-019-0069-0
10.1038/s41572-019-0069-0
Cytokine release syndrome in severe COVID-19
10.1126/science.abb8925 · 2020
10.1016/j.csbj.2021.01.034
10.1016/j.csbj.2021.01.034
Could PROTACs Protect Us From COVID-19?
10.1016/j.drudis.2020.08.007 · 2020
Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2
10.1186/s42269-020-00444-3 · 2020
10.1002/ange.202008835
10.1002/ange.202008835
The SARS-coronavirus infection cycle: A survey of viral membrane proteins, their functional interactions and pathogenesis
2021
10.1038/s41591-020-01227-z
10.1038/s41591-020-01227-z
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
10.1016/j.jiph.2020.07.013 · 2020
10.1039/c7cs00536a
10.1039/c7cs00536a
10.1208/s12248-014-9687-3
10.1208/s12248-014-9687-3
10.1016/j.drudis.2014.10.003
10.1016/j.drudis.2014.10.003
10.1021/acs.jmedchem.7b00318
10.1021/acs.jmedchem.7b00318
Proteolysis targeting chimera (PROTAC): A paradigm-shifting approach in small molecule drug discovery
10.2174/1568026618666181010101922 · 2018
Unresolved referenced work
2021
10.1007/s11030-020-10134-x
10.1007/s11030-020-10134-x
Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery
10.1021/acs.jcim.0c00113 · 2020
Aprotinin Inhibits SARS-CoV-2 Replication
10.3390/cells9112377 · 2020
10.1038/nrd.2017.227
10.1038/nrd.2017.227
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
10.3390/cells9112343 · 2020
10.1016/j.smim.2020.101427
10.1016/j.smim.2020.101427
Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins
10.1016/j.ijbiomac.2020.11.188 · 2021
10.1073/pnas.2016093117
10.1073/pnas.2016093117
Immunomodulatory therapeutic proteins in COVID-19: current clinical development and clinical pharmacology considerations
10.1002/jcph.1729 · 2020
Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins
2021
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
10.1016/s2214-109x(20)30264-3 · doi-reference
10.1080/17460441.2019.1553952
10.1080/17460441.2019.1553952 · doi-reference
Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab
10.4155/fsoa-2017-0013 · doi-reference
Academic drug discovery within the United Kingdom: a reassessment
10.1038/nrd4661 · doi-reference
Rethinking 'academic' drug discovery: the Manchester Institute perspective
10.1016/j.drudis.2014.12.011 · doi-reference
10.1038/nrd.2017.217
10.1038/nrd.2017.217 · doi-reference
10.1038/s41591-019-0670-5
10.1038/s41591-019-0670-5 · doi-reference
Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions
10.1016/j.drudis.2020.12.010 · doi-reference
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
10.1186/s12967-020-02476-9 · doi-reference
Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges
10.1080/17460441.2021.1854221 · doi-reference
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
10.1126/science.abd9909 · doi-reference
10.1016/j.ijbiomac.2020.07.235
10.1016/j.ijbiomac.2020.07.235 · doi-reference
10.1128/aac.00872-20
10.1128/aac.00872-20 · doi-reference
10.1101/2020.05.27.117184
10.1101/2020.05.27.117184 · doi-reference
10.1093/database/bay016
10.1093/database/bay016 · doi-reference
10.1016/j.compbiolchem.2020.107408
10.1016/j.compbiolchem.2020.107408 · doi-reference
10.1101/2020.07.27.223578
10.1101/2020.07.27.223578 · doi-reference
10.1016/j.isci.2020.101642
10.1016/j.isci.2020.101642 · doi-reference
10.1038/s41591-020-0916-2
10.1038/s41591-020-0916-2 · doi-reference
The Emerging Role of Artificial Intelligence in the Fight Against COVID-19
10.1016/j.eururo.2020.09.031 · doi-reference
10.1038/s41598-018-25640-0
10.1038/s41598-018-25640-0 · doi-reference
10.1172/jci89857
10.1172/jci89857 · doi-reference
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
10.1126/sciadv.abe4724 · doi-reference
10.15252/emmm.202012697
10.15252/emmm.202012697 · doi-reference
10.1016/j.bcp.2020.114169
10.1016/j.bcp.2020.114169 · doi-reference
10.15252/emmm.202012817
10.15252/emmm.202012817 · doi-reference
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
10.1016/s0140-6736(20)30304-4 · doi-reference
10.1021/acs.jpclett.0c02421
10.1021/acs.jpclett.0c02421 · doi-reference
10.3390/ijms21113793
10.3390/ijms21113793 · doi-reference
10.1101/2020.08.28.271957
10.1101/2020.08.28.271957 · doi-reference
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
10.1126/science.abb4489 · doi-reference
10.1021/acsptsci.0c00130
10.1021/acsptsci.0c00130 · doi-reference
10.1038/s41586-020-2223-y
10.1038/s41586-020-2223-y · doi-reference
QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2
10.1002/minf.202000113 · doi-reference
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
10.1126/sciimmunol.abc5367 · doi-reference
Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review
10.1007/s11130-020-00861-9 · doi-reference
10.1016/j.drup.2020.100719
10.1016/j.drup.2020.100719 · doi-reference
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
10.1021/acsptsci.0c00131 · doi-reference
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches
10.1016/j.meegid.2020.104451 · doi-reference
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro
10.1371/journal.pcbi.1008489 · doi-reference